PURPOSE: This paper describes the ability of miRNA value predict oncological outcomes in CRC patients and correlates to clinical and pathologic variables.
Introduction
Colorectal cancer (CRC) is the third most common malignancy in Western countries and, despite advances in diagnosis and treatment, it is the second leading cause of cancer death in the United States 1 . In Brazil, CRC is the fourth most common malignancy, and more than 32000 new cases of the disease were estimated for 201 2 .
If detected at an early stage, the prognosis of the disease is considered good, and 5-year survival rate may reach 65%.
However, even with optimal treatment, 40-50% of patients may experience recurrence of the disease during follow-up 3 .
Classic predictors of tumor behavior include tumor grade, TNM stage, positive surgical margins, histological subtype, obstructive or perforated tumors, lymphovascular and perineural invasion, locally advanced disease and less than 12 lymph nodes recovered to analysis [4] [5] [6] .
Micro RNAs (miRNA) are single-stranded molecules of 20-24 nucleotides in length, considered as regulators of gene expression at a post-transcriptional level 7, 8 . They are involved in several biological processes and have recently been associated with carcinogenesis, therapeutic response, and prognosis 9 ( Figure   1 ). Micro RNAs can be divided in oncogenic miRNA (Oncomirs), those related to tumor development, and tumor suppressor miRNA, that usually prevent the development of malignancies by inhibition of proto-oncogenes 10 .
The dosage of serum levels of some miRNAs may prove to be a valuable tool to diagnose CRC or to detect recurrence 12 .
The primary objective of this study analyzes the serum levels of miR-21, miR-34a and miR-126 in patients with CRC and make a correlation with prognosis variables.
Methods
After approval by the Research Ethics Committee, a prospective study was performed with 37 consecutive CRC patients undergoing curative surgery at Clinics Hospital-University of São Paulo (Ribeirão Preto, SP, Brazil), in April 2008-February 2009.
All patients provided informed written consent for enrollment in the study. Exclusion criteria included genetic CRC related to genetic syndromes, non-curative surgery, previous chemotherapy and radiotherapy and refusal to provide written informed consent.
Variables collected from medical records included gender, age, tumor site, histologic subtype, pre-operative CEA, TNM staging (AJCC, 7th edition, 2010), recurrence site and overall survival.
Blood samples were collected from CRC patients during the surgery and from 7 healthy volunteers under 50 years old without CRC or any known genetic syndrome. All samples were stored in sterile bottles with Ethylenediaminetetraacetic acid and maintained at -80ºC degrees.
Nucleic acid extraction and RNA quantification
Serum or plasma microRNAs were extracted using the miRNeasy Mini Kit ® (Qiagen, Hilden, Germany) 13 . Plasma samples were lysed with TRIzol 
Results
The main clinical and pathological characteristics of the patients are described in Table 1 . The expression of miR-21 was lower in the colorectal cancer group (P< 0.001) and in colorectal cancer patients younger than 60 years old (P=0.01). No difference was noted comparing subjects with or without recurrence (P=0.06) and among TNM staging subgroups (P=0.32). There was no correlation between miR-21 expression, CEA levels, and overall survival.
MicroRNA-34a was underexpressed in subjects with CRC (P<0.001) and patients younger than 60 years (P<0.001). No statistical difference was noted comparing patients with or without recurrence (P=0.74) and between TNM staging groups (P=0.22).
There was no correlation between miR-34a expression, CEA levels, and overall survival.
The circulating levels of miR-126 were lower in CRC subjects (P<0.001) and in patients under 60 years (P<0.001). No difference was noted comparing subjects with or without recurrence (P=0.89) and among TNM staging subgroups (P=0.31). There was no correlation between miR-126 expression, CEA levels and global survival.
The expression of each microRNA according to CEA levels, TNM staging group and recurrence are illustrated in figure 2 .
FIGURE 2 -Expression of microRNAs (mean ± standard deviation) according to age groups, CEA levels, TNM staging and recurrence
Discussion
The full understanding of miRNAs role on carcinogenesis is a laborious task since their function may vary according to the target tissue and may be influenced by population and environmental characteristics 14, 15 . Some tumor-specific alterations in nucleic acids promise non-invasive biomarkers that can be detected in the plasma of patients 12, 16 .
The miR-21 inhibits the expression of tumor suppressive genes and induces cell proliferation 17 . An overexpression of miR-21 has been found in breast, pancreas, prostate and colorectal cancerand has been linked to more advanced TNM stages, lower cellular differentiation decreased overall survival and reduced disease-free survival [18] [19] [20] . This correlation with a poorer prognosis could help determine patients who would benefit from a personalized treatment 21 . The present study found no relation between miR-21 and CRC prognosis. This finding could be explained by a wide variation in serum levels of miR-21, in patients with colon and rectal cancer 22, 23 .
MicroRNA-34a can act as a tumor suppressor by regulating proliferation, invasion, metastasis and apoptosispatients and human colorectal cancer 5-fluorouracil-resistant DLD-1 cells 24, 25 . Furthermore, when valued tissue expression, 36% of colon cancer samples showed decreased expression of miR-34a compared to noncancerous colon specimen 26 . However, the precise correlation between miR-34 levels and prognosis is still under investigation 27 .
A high expression of miR-126 inhibited cell proliferation, migration, and invasion, suggesting that it may act as a tumor suppressor 28 . Low expression of miR-126 have been related to poor prognosis in colon cancer patients 29, 30 . This finding was not confirmed by the present study. Further investigation is necessary to identify specific microRNAs that can act as prognostic tools in colorectal cancer.
Conclusion
This study suggests that the expression of miR-21, miR34a and miR-126 was lower in the CRC group and CRC subjects younger than 60 years old. No associations with CEA values, TNM staging, and histological subtype were noted and, contrary to what has been evidenced, the present study found no association of those biomarkers with poor prognosis.
